AI Verdict
AAPL has stronger fundamentals based on our AI analysis.
PCRX vs AAPL Fundamental Comparison
| Metric | PCRX | AAPL |
|---|---|---|
| Revenue | $726.4M | $143.8B |
| Net Income | $7.0M | $42.1B |
| Net Margin | 1.0% | 29.3% |
| ROE | 1.0% | 47.7% |
| ROA | 0.6% | 11.1% |
| Current Ratio | 4.54x | 0.97x |
| Debt/Equity | 0.54x | 1.00x |
| EPS | $0.16 | $2.84 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
PCRX vs AAPL: Frequently Asked Questions
Is PCRX or AAPL a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), AAPL has stronger fundamentals. PCRX is rated HOLD (65% confidence) while AAPL is rated BUY (87% confidence). This is not investment advice.
How does PCRX compare to AAPL fundamentally?
Pacira BioSciences, Inc. has ROE of 1.0% vs Apple Inc.'s 47.7%. Net margins are 1.0% vs 29.3% respectively.
Which stock pays higher dividends, PCRX or AAPL?
PCRX has a dividend yield of N/A or no dividend while AAPL has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in PCRX or AAPL for long term?
For long-term investing, consider that PCRX has HOLD rating with 65% confidence, while AAPL has BUY rating with 87% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about PCRX vs AAPL?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For PCRX vs AAPL, the AI consensus favors AAPL based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.